Cardiovascular Disease Medication Administration Methods" and "flow Restricting Stent-graft

This patent portfolio, assigned to Aorto Medical LLC, covers a new and innovative stent-graft, and is available for sale or license through IPApproach.

Foreign Counterparts

11

Assignee

Aorto Medical LLC

Availability

For Sale or License

Patents Included

• AU 2020221388 B2
• KR 102434371 B1
• BR 112021016124 A2
• CA 3129454 C
• CN 113573667 B
• MX 393391 B
• CN 115517810 A
• EP 3923862 A4
• JP 7162797 B2
• JP 2022180497 A
• AU 2022215946 A9

Technology Highlights

• The invention provides a therapeutic solution for the prevention of urinary incontinence. The disclosed stent-graft is configured for insertion into a patient's urethra and is designed to inhibit the passage of fluid until the upstream fluid pressure reaches a predetermined threshold.
• The invention includes a stent frame defining a cavity that extends from a proximal opening of the stent-graft to a distal opening thereof. Accordingly, a fluid (e.g., blood) flows into the cavity through the proximal opening and exits through the distal opening.
• The invention provides, among other embodiments, a stent-graft having a central portion with a greater width than the left and right flow portions, thereby facilitating a more uniform distribution of blood to each of the patient's legs.
• The invention is configured to include a flow-restricting section, or lobular obstruction. Within this section, the cross-sectional area of the cavity decreases from a proximal cross-sectional area corresponding to the area at the proximal end opening (e.g., having a diameter between 20 and 42 mm) to a minimum cross-sectional area, and then increases from the minimum cross-sectional area to a distal cross-sectional area corresponding to the area at the distal end opening.
• The invention is configured such that, at the minimum cross-sectional area, the stent frame applies an outward fixation force to at least 50% of the aortic circumference. This increased fixation force, compared to an example stent-graft incorporating indentations, further enhances positional stability and helps limit movement of the stent-graft when deployed within a patient's aorta.
• The invention includes an outer perimeter of the stent frame at the flow ends that enhances manufacturing efficiency. For example, stent-grafts incorporating indentations require more complex folding patterns during fabrication. By eliminating such indentations, the example stent-graft can be manufactured more easily and efficiently, reducing production time and complexity.
• The invention is configured to permit a greater volume of blood flow through one flow end relative to the other and a higher proportion of blood is directed to one of the patient's legs compared to the other if desired.
• The invention provides an apparatus configured for insertion into a patient's urethra. In this embodiment, the example stent-graft 1000 is smaller in size than stent-grafts (e.g., stent-grafts 100 and 300) that are adapted for placement within the abdominal aorta for the treatment of congestive heart failure.
• The invention provides, among other embodiments, a stent-graft having a constant wire frame perimeter throughout the length of the apparatus, which would allow for flow area adaptation at the minimum cross-sectional area in a wide variety of aortic diameter sizes.
• The invention provides, among other embodiments, a stent-graft having a constant wire frame perimeter throughout the length of the apparatus, which would allow for mechanical dilation/expansion of the flow area at the minimum cross-sectional area in order to safely and adequately reverse the flow-restricting effect of the device if required following heart transplantation or left ventricular assist device implantation.
• The invention provides therapeutic support for patients with overactive bladder, a form of urinary incontinence. Patients have two urinary sphincters, a first sphincter located at the bladder neck and a second positioned further along the urethra. The first urinary sphincter opens to permit the passage of urine once a sufficient volume and pressure have accumulated within the bladder.
• The invention provides a flow-diverting apparatus having any suitable cone-shaped, hourglass-shaped, or lobe-shaped configuration, which may include pockets expandable by fluid or gas. The apparatus is configured to partially occlude flow through a vessel, such as the infrarenal aorta or a vessel downstream of the infrarenal aorta.
• The invention provides any implanted flow-diverting apparatus that can help mitigate or eliminate the side effects a patient may experience when the dosage of a beta-blocker, angiotensin receptor blocker, angiotensin-converting enzyme (ACE) inhibitor, chymase inhibitor, or a combination of these therapies is increased above a baseline level, thereby allowing for the administration of higher therapeutic dosages.
• The invention provides novel titration methods for adjusting the dosage of one or more medications prescribed to a patient with cardiovascular disease by integrating the therapeutic use of a flow-diverting apparatus with the administration of such medications.
• The invention elevates renal blood pressure by increasing blood flow proximal to the implanted flow-diverting apparatus, thereby restoring higher renal perfusion pressure. This increase in perfusion elevates intraglomerular pressure, resulting in an enhanced glomerular filtration rate and urine output, ultimately reducing the severity of fluid retention-related symptoms commonly observed in patients with heart failure.
• The invention generates a localized increase in blood pressure proximal to, or upstream of, the flow-diverting apparatus, which can also enhance cerebral perfusion and thereby alleviate symptoms of upper-body hypotension, such as dizziness and confusion.
• The invention increases urine output, allowing for the reduction or down-titration of diuretic doses (e.g., furosemide) that would otherwise be required to achieve optimal diuresis. This approach also reduces the potential for side effects associated with diuretic therapy by enabling effective treatment with lower medication doses.
• The invention facilitates increased blood pressure in the renal artery branches, which can help minimize or eliminate the side effects experienced by a patient when the dosage of one or more administered medications is increased.

Overview

IPApproach LLC ,is pleased to present the attached exclusive patent applications for sale or license "Cardiovascular disease medication administration methods" and "Flow restricting stent-graft" which includes U.S. Patent US 20,240,123,204 A1 and US 20,220,125,571 A1 and their foreign counterparts AU 2020221388 B2; KR 102434371 B1; BR 112021016124 A2; CA 3129454 C; CN 113573667 B; MX 393391 B; CN 115517810 A; EP 3923862 A4; JP 7162797 B2; JP 2022180497 A and AU 2022215946 A9 assigned to Aorto Medical LLC. The IP relates to a new and innovative stent-graft. The stent-graft may be tapered in order to help create a controlled, proximal perfusion gradient of aortic blood to achieve more complete renal artery filling and direct a larger volume of blood to the kidneys, particularly in congestive heart failure patients and also relates to cardiovascular disease treatment. More specifically, the present application provides methods of increasing or decreasing the medication dosages prescribed to cardiovascular disease patients through the use of any implanted flow diverting apparatus.

The technology disclosed provides the following advantages:

Listing updated August 21, 2026

IPApproach lists patents and portfolios where the seller has not requested anonymity or confidentiality. Patent numbers link to public records on Google Patents.